Skip to main content

Danaher Corporation Biotechnology revenue

  • DHR · NYSE
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$233.02+0.37%Close 13 Nov 2026 · Market value $162.9B

Biotechnology revenue at Danaher Corporation came to $1.8B for the quarter to 25 Sep 2026, up 0.5% from a year earlier.

As Danaher Corporation reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 21 Oct 2026.

By quarter

$1.8BDec 2023$1.5BMar 2024$1.7BJun 2024$1.7BSep 2024$1.9BDec 2024$1.6BMar 2025$1.9BJun 2025$1.8BSep 2025$2.0BDec 2025$1.8BMar 2026$1.9BJun 2026$1.8BSep 2026
Danaher Corporation Biotechnology revenue, every reported period
Period endingBiotechnology revenueChange on a yearFiled
25 Sep 2026$1.8Bup 0.5%21 Oct 2026
26 Jun 2026$1.9Bup 3.8%21 Jul 2026
27 Mar 2026$1.8Bup 11.5%21 Apr 2026
31 Dec 2025$2.0Bup 8.8%24 Feb 2026
26 Sep 2025$1.8Bup 8.8%21 Oct 2025
27 Jun 2025$1.9Bup 8.0%22 Jul 2025
28 Mar 2025$1.6Bup 5.8%22 Apr 2025
31 Dec 2024$1.9Bup 6.3%20 Feb 2025
27 Sep 2024$1.7Bdown 0.7%22 Oct 2024
28 Jun 2024$1.7Bdown 9.1%23 Jul 2024
29 Mar 2024$1.5Bdown 18.2%23 Apr 2024
31 Dec 2023$1.8Bdown 20.9%21 Feb 2024
29 Sep 2023$1.7Bdown 18.9%24 Oct 2023
30 Jun 2023$1.9Bdown 16.8%25 Jul 2023
31 Mar 2023$1.9Bdown 15.9%25 Apr 2023
31 Dec 2022$2.2B—22 Feb 2023
30 Sep 2022$2.1B—20 Oct 2022
1 Jul 2022$2.3B—21 Jul 2022
1 Apr 2022$2.2B—21 Apr 2022

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Danaher Corporation: Recurring revenue · Nonrecurring revenue · Diagnostics revenue · Life Sciences revenue · North America revenue · High-growth markets revenue · Western Europe revenue · financial statements

Every KPI and segment of DHR, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.